Ezetimibe/simvastatin (Vytorin) vs Rosuvamibe
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: HMG-CoA reductase / NPC1L1 · full Atherosclerotic Cardiovascular Disease pipeline
Ezetimibe/simvastatin (Vytorin)
Marketed by Organon
NCT00202878 · Phase 3 · completed
The trial randomly assigned 18,144 participants to Vytorin or simvastatin, used triple blinding, and included an active comparator. Its primary clinical endpoint occurred in 32.72% of the Vytorin group versus 34.67% of the simvastatin group; the difference was statistically significant (hazard ratio 0.936, 95% CI 0.887–0.988; p=0.016).
Reported efficacy
Time to First Occurrence of Cardiovascular Death, Major Coronary Event, or Non-fatal Stroke (Kaplan-Meier Estimate of Percentage of Participants Experiencing a Qualifying Event) (Up to approximately 9 years): Time to First Occurrence of Cardiovascular Death, Major Coronary Event, or Non-fatal Stroke (Kaplan-Meier Estimate of Percentage of Participants Experiencing a Qualifying Event) (Up to approximately 9 years): Ezetimibe/Simvastatin 32.72% (95% CI 31.63 to 33.85) vs Simvastatin 34.67% (95% CI 33.56 to 35.81) (met)
Result source: NCT00202878
Rosuvamibe
Marketed by Yuhan Corporation and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Atherosclerotic Cardiovascular Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Ezetimibe/simvastatin (Vytorin) | Rosuvamibe |
|---|---|---|
| LDL-C, % change | -49.3% vs -38.0%vs AtorvastatinNCT004967303 other results
| —Not reported |
| Non-HDL-C, % change | —Not posted · NCT00110435 | —Not reported |
| ApoB, % change | —Not posted · NCT00110435 | —Not reported |
| Lp(a), % change | —Not posted · NCT00110435 | —Not reported |
| 3-point MACE (% with event) | —Not posted · NCT00110435 | —Not reported |
LDL-C, % change
- Ezetimibe/simvastatin (Vytorin)
- -49.3% vs -38.0%vs AtorvastatinNCT00496730
3 other results
- -44.7% vs -27.1% NCT00762164
- -53.6% vs -38.3% NCT00110435
- -57.6% vs -50.9% NCT00110435
- Rosuvamibe
- —Not reported
Non-HDL-C, % change
- Ezetimibe/simvastatin (Vytorin)
- —Not posted · NCT00110435
- Rosuvamibe
- —Not reported
ApoB, % change
- Ezetimibe/simvastatin (Vytorin)
- —Not posted · NCT00110435
- Rosuvamibe
- —Not reported
Lp(a), % change
- Ezetimibe/simvastatin (Vytorin)
- —Not posted · NCT00110435
- Rosuvamibe
- —Not reported
3-point MACE (% with event)
- Ezetimibe/simvastatin (Vytorin)
- —Not posted · NCT00110435
- Rosuvamibe
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Rosuvamibe: no structured comparison results are available for Atherosclerotic Cardiovascular Disease.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Ezetimibe/simvastatin (Vytorin): 4 of 4 rows · Rosuvamibe: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Ezetimibe/simvastatin (Vytorin) |
|---|---|
| Dropout rate | 24.3%Ezetimibe/Simvastatina NCT00202878 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3 show 5 more results—Ezetimide/Simvastatin NCT00202878 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3 4.6%10/20 mg NCT00496730 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3 12.1%10/20 mg NCT00654628 · Phase 4 · registry result, not featured evidence 17.6%10/80 mg divided into 4 NCT00762164 · Phase 4 · registry result, not featured evidence 14.4% NCT00442897 · Phase 4 · registry result, not featured evidence |
| Discontinued due to AEs | —Ezetimibe/Simvastatina NCT00202878 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3 show 5 more results—Ezetimide/Simvastatin NCT00202878 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3 —10/20 mg NCT00496730 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3 5.2%10/20 mg NCT00654628 · Phase 4 · registry result, not featured evidence —10/80 mg divided into 4 NCT00762164 · Phase 4 · registry result, not featured evidence 0.8% NCT00442897 · Phase 4 · registry result, not featured evidence |
| Serious AEs | —Ezetimibe/Simvastatina NCT00202878 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3 show 5 more results40.1%Ezetimide/Simvastatin NCT00202878 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3 —10/20 mg NCT00496730 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3 0.6%10/20 mg NCT00654628 · Phase 4 · registry result, not featured evidence 0%10/80 mg divided into 4 NCT00762164 · Phase 4 · registry result, not featured evidence 0% NCT00442897 · Phase 4 · registry result, not featured evidence |
| Most frequent reported AEs | a arthralgia 11% myalgia 10.5% pain in extremity 10.5% NCT00202878 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3 show 4 more results10/20 mg hypercholesterolaemia 4.8% hypertriglyceridaemia 3.2% abdominal pain upper 1.6% NCT00496730 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3 10/20 mg myalgia 4% upper respiratory infection 4% increased creatine phosphokinase (cpk) 3.5% NCT00654628 · Phase 4 · registry result, not featured evidence 10/80 mg divided into 4 muscle pain-myalgia 11.8% NCT00762164 · Phase 4 · registry result, not featured evidence upper respiratory tract infection 3.7% headache 1.9% transaminases increased 1.9% NCT00442897 · Phase 4 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 3 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Ezetimibe/simvastatin (Vytorin)
show 3 more results
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
+ 2 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ezetimibe/simvastatin (Vytorin)'s landscape · Rosuvamibe's landscape